Increasing Prevalence and Incidence of COPD to Augment the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include cough, breathing difficulty, wheezing, and mucus production. COPD is a progressive lung disease that includes refractory asthma emphysema, and chronic bronchitis. The major causes behind the occurrence of COPD include alpha-1 deficiency-related emphysema, secondhand smoke, air pollution, smoking, and others. Moreover, COPD is a major health concern affecting a large number of individuals worldwide. The disease burden is rising, and thus, the need for COPD management, which is expected to drive the market.
With proper management, most people can achieve good symptom control and quality of life, and reduce the risk of other associated conditions such as lung cancer and heart disease. Increasing prevalence and incidence of COPD and awareness efforts carried out by individual organizations are expected to propel the growth of the chronic obstructive pulmonary disease treatment market. According to the American Lung Association, over 16.4 million people in the United States have been diagnosed with COPD, while millions more may have the disease without even knowing it. COPD is the third leading cause of death in the U.S. Organizations such as the Centers for Disease Control and Prevention, American Thoracic Society, COPD Foundation, and World Health Organization work towards raising awareness among people about COPD.
Moreover, the National Institutes of Health runs an initiative, named COPD Learn More Breathe Better, and celebrates November as a national COPD awareness month. The above-mentioned factors are expected to drive the growth of the market. An increase in product launches and ongoing research and development is also expected to fuel market growth. For instance, in March 2019, Novartis launched Seebri Breezhaler and Ultibro Breezhaler in China for the treatment of COPD. Whereas, in April 2019, Cipla launched Niveoli, an inhaler for people suffering from COPD and asthma (obstructive airway diseases).
Moreover, the National Institutes of Health runs an initiative, named COPD Learn More Breathe Better, and celebrates November as a national COPD awareness month. The above-mentioned factors are expected to drive the growth of the market. An increase in product launches and ongoing research and development is also expected to fuel market growth. For instance, in March 2019, Novartis launched Seebri Breezhaler and Ultibro Breezhaler in China for the treatment of COPD. Whereas, in April 2019, Cipla launched Niveoli, an inhaler for people suffering from COPD and asthma (obstructive airway diseases).

Comments
Post a Comment